Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 811 results for "bristol myers squibb"

Bristol-Myers' Revolutionary Cancer Drug Suffers A Big Blow

Bristol-Myers Squibb 's ( NYSE:BMY ) Opdivo is approved to treat some patients who see their lung cancer return following chemotherapy, but a key trial evaluating Opdivo's use in previously untreated patients recently came up short. The news caused ... Motley Fool, 2 weeks ago
[x]  

276 images for bristol myers squibb

PharmaVOICE, 1 week ago
Octafinance, 1 week ago
Bidness Etc, 5 days ago
Bidness Etc, 1 week ago
Nasdaq, 2 weeks ago
Bidness Etc, 2 weeks ago
Nasdaq, 2 weeks ago
Nasdaq, 2 weeks ago
Nasdaq, 3 weeks ago
Share Market Updates, 2 days ago
Bidness Etc

Jacobs & Co. CA Has $1,719,000 Stake in Bristol-Myers Squibb Co. (BMY)

Jacobs & Co. CA lowered its stake in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 0.2% during the second quarter, Holdings Channel reports. The institutional investor owned 23,384 shares of the biopharmaceutical company's stock after selling 39 ...
 Mideast Time2 weeks ago Smith Affiliated Capital Corp. Has $170,000 Stake in Bristol-Myers Squibb Co. (BMY)  Zolmax News2 weeks ago Gulf International Bank UK Ltd Has $37,042,000 Position in Bristol-Myers Squibb Co. (BMY)  Mideast Time2 weeks ago Sanford C. Bernstein Reiterates Market Perform Rating for Bristol-Myers Squibb Co. (BMY)  American Banking News2 weeks ago
[x]  
Bloomberg

Bristol-Myers Squibb's Immunotherapy Drug Opdivo Falls Short In Clinical Trials

 Kaiser Health News2 weeks ago Analysts: Failed clinical trial could cost Bristol-Myers $4B in lost sales  Seeking Alpha3 weeks ago Bristol-Myers Falls Most in 14 Years as Drug Misses Goal: Chart  Bloomberg3 weeks ago Bristol-Myers Slumps as Drug Misses Key Lung-Cancer Goal (1)  La Repubblica3 weeks ago
[x]  
Investor's Business Daily

Merck's Keytruda fortunes look even better as doctors digest Opdivo's lung cancer failure

Analysts hiked their estimates for Merck & Co.'s ($MRK) Keytruda sales last week after a Bristol-Myers Squibb ($BMY) rival fell short in a key lung cancer study. But if new doctor surveys prove out, they may need to jack up those estimates even ...
 FiercePharma1 week ago Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo  Reuters3 days ago Bristol's Opdivo Fall-Out Brings Others Into Play  Seeking Alpha2 weeks ago Bristol-Myers Stock Plunges As Opdivo Fails; Merck Up  Investor's Business Daily3 weeks ago

The Bristol-Myers Squibb Drug Bust

As the dust starts to settle after the shocking news that Bristol-Myers Squibb's (NYSE: BMY ) small-cell lung cancer drug, Opdivo, failed its Phase 3 trial, now is the time to start thinking rationally about the long-term investment opportunities in ...
 Seeking Alpha2 weeks ago Bristol-Myers: Lung Cancer Failure Too Significant To Stay Bullish  Minyanville2 weeks ago Bristol-Myers says CheckMate cancer drug failed to meet primary endpoint  Seeking Alpha3 weeks ago Bristol-Myers Craters on Cancer Drug Trial Failure  Marketplace3 weeks ago
[x]  

Cramer says he's shocked like everyone else on Bristol-Myers drug results

day that he was shocked after Bristol-Myers Squibb announced its lung cancer drug failed in a late-stage study. Shares of Bristol-Myers dropped more than 17 percent Friday morning while competitors, such as Merck with different versions of the ...
 CNBC3 weeks ago Blockbuster cancer treatment fails in key study, Bristol-Myers shares plunge  CTV News3 weeks ago BRISTOL MYERS SQUIBB : -Myers drug fails lung cancer study, shares plunge  4 Traders3 weeks ago Bristol-Myers drug fails lung cancer study, shares plunge  SiliconValley.com3 weeks ago
[x]  

BRIEF-Moodys says Bristol-Myers Squibbs lung cancer trial result a major setback

Aug 5 Moody's on Bristol-Myers Squibb: * Moody's: Bristol's lung cancer trial result a major setback * There is no impact on Bristol-Myers Squibb's A2/PRIME-1 ratings or stable rating outlook Source text for Eikon: Further company coverage: ...
 Reuters UK3 weeks ago Merck Could Gain from Bristol's Poor Drug Trial Results  Yahoo! Finance3 weeks ago

Bristol Myers: Science Trumps The Headlines

Since last Friday, Bristol-Myers Squibb (NYSE: BMY ) has dropped nearly 19% after reporting that Opdivo failed to meet its primary endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer ...
 Seeking Alpha2 weeks ago
Motley Fool

After Opdivo's Failure, Is Merck a Better Buy Than Bristol-Myers?

Image source: . Bristol-Myers Squibb 's ( NYSE:BMY ) Opdivo failed to deliver the goods in a key lung cancer trial, causing Bristol-Myers' shares to plummet. The failure also prompted investors to rush into Bristol-Myers Squibb's competitors, ...
 Motley Fool2 weeks ago
[x]  

Five Prime Therapeutics Could Be The Ace Up The Sleeve Of Bristol-Myers Squibb

As investors begin to digest what happened to Bristol-Myers Squibb (NYSE: BMY ) failed Phase 3 trial of Opdivo in advanced non-small cell lung cancer, 2 takeaways are becoming obvious. First, Bristol-Myers tried for a homerun, when all they needed ...
 Seeking Alpha2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - bristol myers squibb
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less